611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Researchers ID Microbiome Genes Tied to AsthmaPlasma Rich in Growth Factors May Promote Hair RegenerationBest Practice Advice Issued for Hep B Vaccination, ScreeningIs a Common Shoulder Surgery Useless?NAFLD Linked to Smaller Total Cerebral Brain VolumeSalivary miRNAs Can ID Duration of Concussion SymptomsHigh Salt Intake Impacts Gut MicrobiomeSevere Psoriasis May Make Diabetes Increasingly LikelyNAFLD Linked to Increased Cancer Incidence RateSpinal Cord Stimulation May Reduce Neuropathic PainBrain Glucose Responses Diminish With Diabetes, ObesityMany Health Care Providers Work While SickIntensive BP Control Lacks Benefit in Chronic Kidney DiseaseGulf War Illness, Chronic Fatigue Syndrome Are Distinct Disorders: Study'Boomers' Doing Better at Avoiding Eye Disease of AgingAHA: Supervised Exercise Ups 6-Minute Walking Distance in PADAccurate Diagnosis Seen With Photographs of Skin ConditionsModel Predicts Development of Chronic Kidney DiseaseNew Hemophilia Treatment Stems Bleeding EpisodesHealth Tip: If There's a Wildfire NearbyPeanut Patch Found Safe, Effective for Treating AllergiesWhy a Headache Feels So DrainingStaying Active May Lower Odds for GlaucomaHow to Do a Skin Cancer Body CheckCan Treating Gum Disease Keep Blood Pressure in Line?AHA/ACA Present New Blood Pressure GuidelinesAAO: Higher Exercise Intensity Tied to Reduced Risk of GlaucomaAAO: Intranasal Tear Neurostimulator Safe for Dry EyeOutcomes for Atrial Fibrillation Similar With Dabigatran, WarfarinOutbreaks Linked to Drinking Water Mainly Due to LegionellaIs Low-Dose Aspirin Right for You After Surgery?Swings in Blood Pressure Can Pose Long-Term DangersAHA: Acetylcysteine, Sodium Bicarbonate Don't Cut Renal RiskBinge-Watchers, Beware: Long TV Time Poses Clot RiskObesity to Blame for Epidemic of Knee Dislocations, ComplicationsThe Heart Risks of a Desk JobCould Fish Oil, Vitamin D Help Ease Lupus?Smog May Harm Your Bones, TooOverlapping Surgery Appears Safe in Neurosurgical ProceduresAdding Exercise to Compression Therapy Promising for Leg UlcersRisk of End-Stage Renal Disease Low With Type 1 DiabetesHealth Tip: What's Healthy Blood Pressure?'Old' Lungs May Be Good Transplant OptionsHPV Vaccine Linked to Drop in Cases of Rare Childhood DiseaseNeurologic Abnormalities Identified After West Nile VirusSodium Oxybate Promising for Parkinson's, Daytime SleepinessDrop in Incidence of End-Stage Renal Disease Due to DiabetesThese Foods May Help Ease Rheumatoid Arthritis PainWhat Really Works to Fight a Stubborn Cough?West Nile's Long-Term Bite: Impact on Brain May Last Years
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Warfarin, Rivaroxaban Similarly Safe, Effective


HealthDay News
Updated: Sep 12th 2017

new article illustration

TUESDAY, Sept. 12, 2017 (HealthDay News) -- For cases of mild atrial fibrillation (AF)-related acute ischemic stroke, rivaroxaban and warfarin are similarly safe and effective at preventing recurrent stroke, according to a study published online Sept. 11 in JAMA Neurology.

Keun-Sik Hong, M.D., from Inje University in Goyang, South Korea, and colleagues compared rivaroxaban or warfarin sodium for prevention of early recurrent stroke in patients with AF-related acute ischemic stroke. Patients were randomized (1:1) to receive rivaroxaban (10 mg/day for five days followed by 15 or 20 mg/day; 95 participants) or warfarin with a target international normalized ratio of 2.0 to 3.0 (88 participants), for four weeks.

The researchers found that the two groups showed no differences in the primary composite end point (P = 0.49) or its individual components: new ischemic lesion (relative risk [RR], 0.83; 95 percent confidence interval, 0.54 to 1.26; P = 0.38) or new intracranial hemorrhage (RR, 1.10; 95 percent confidence interval, 0.70 to 1.71; P = 0.68). Each group had one clinical ischemic stroke. All new intracranial hemorrhages were asymptomatic hemorrhagic transformations. Rivaroxaban was associated with reduced hospitalization length compared with warfarin (median, 4.0 days versus 6.0 days; P < 0.001).

"In mild AF-related acute ischemic stroke, rivaroxaban and warfarin had comparable safety and efficacy," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Bayer, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)